window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 27, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

biotech leadership

  • Healthcare leadership,Mergers & Acquisitions,Movers & Shakers,Pharmaceuticals and therapeutics

    Genmab appoints Margarida Duarte as general manager for Europe and emerging markets

    Genmab has appointed Margarida Duarte as general manager, Europe and [...]

    April 8, 2026
  • Biotech,Drug discovery,Healthcare leadership,Movers & Shakers,Research & Development,Startups and innovations,Technology and platforms

    Proxygen appoints Chiara Conti as chief scientific officer to support move into clinical-stage development

    Proxygen has appointed Chiara Conti as chief scientific officer, as [...]

    April 2, 2026
  • Healthcare leadership,Movers & Shakers

    Abselion hires Dale Gordon as chair to support growth push

    Abselion has appointed Dale Gordon as chair as the company [...]

    March 23, 2026
  • Biologics & Biosimilars,Biotech,Cell & Gene Therapy,Clinical Development,Healthcare leadership,Movers & Shakers,Pharmaceuticals and therapeutics

    iXCells names Steve Smith CEO to advance human iPSC preclinical services

    iXCells Biotechnologies has appointed Steve Smith as chief executive officer, [...]

    January 14, 2026
  • Biotech,Central Nervous System,Healthcare leadership,Movers & Shakers,Neurosciences

    AstronauTx appoints Adam Rosenberg as Chair of the Board

    AstronauTx has appointed Adam Rosenberg as chair of the board, [...]

    January 14, 2026
  • Clinical Development,Clinical Trials,Movers & Shakers,Oncology,Research & Development

    Syncromune appoints Stephen Dale as Chief Medical Officer

    Syncromune has appointed Stephen Dale as chief medical officer, strengthening [...]

    January 14, 2026
  • Artificial Intelligence,Biologics & Biosimilars,Cell & Gene Therapy,Clinical Development,Drug Development,Movers & Shakers,Pharmaceuticals and therapeutics

    Formation Bio expands leadership team with biotech and pharma veterans to accelerate AI-driven drug development

    Formation Bio, the AI-native pharmaceutical company advancing a new model [...]

    September 23, 2025
  • Cell & Gene Therapy,Clinical Trials,Movers & Shakers,Rare Diseases

    Ascidian boosts RNA therapy push with key hire and expert board for Stargardt trial

    Ascidian Therapeutics has appointed Murray Abramson as chief development officer. [...]

    June 30, 2025
  • Biologics & Biosimilars,Precision medicine

    Enhanced Genomics appoints biotech veteran Dietrich Stephan as chair to drive next-gen target discovery

    Enhanced Genomics has appointed leading biotechnology entrepreneur Dietrich Stephan as [...]

    June 12, 2025
  • Cell & Gene Therapy,Drug Development,Technology and platforms

    Commit Biologics launches Scientific Advisory Board to accelerate BiCE platform development

    Commit Biologics has announced the formation of a Scientific Advisory [...]

    June 9, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top